Apogee Therapeutics Reports $0 Revenue, $(4.22) EPS in 2025 10-K Amid Heavy R&D Investment
APGE has more than doubled off its 52-week low of $26.2.
Summary
Apogee Therapeutics filed its 2025 10-K, reporting no product revenue and a net loss of $255.8 million, resulting in an EPS of $(4.22). The company incurred a loss from operations of $285.6 million, reflecting substantial investment in its clinical and manufacturing programs. For a clinical-stage biotechnology company, $0 revenue and significant losses are typical as it invests heavily in its pipeline. This annual filing provides a comprehensive look at the company's financial performance, highlighting its continued focus on advancing multiple antibody programs, including zumilokibart. Investors will monitor the company's cash burn rate and its ability to continue funding its clinical trials as it progresses towards potential commercialization.
At the time of this announcement, APGE was trading at $69.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $26.20 to $84.56. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Unknown.